Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (PSMA) (FOLH1) and CD3 (T-cell receptor complex) (CD3E) · developed by Janux Therapeutics
JANX007 is a protease-activated T-cell engager that binds PSMA on tumor cells and CD3 on T-cells, with a peptide mask and albumin-binding domain that are released when a tumor protease cleaves its linker in the tumor microenvironment. It is being studied in prostate cancer, including castration-resistant and metastatic disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07813637 | Phase 1 | Prostate Cancer | Recruiting | JANX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Castration-Resistant Prostate Cancer (CRPC)Metastatic Castration-Resistant Prostate Cancer PatientsMetastatic Prostate CancerProstate Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the JANX page.
See JANX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JANX catalysts and pipeline →